Talking to Your Healthcare Team About Treatment for EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

Talking to Your Healthcare Team About Treatment for Early-Stage EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

This podcast is for people who have early-stage EGFR-mutated non-small cell lung cancer, or anyone who wants to learn more about testing and treatment for it. The goal of this patient education activity is to help people who are living with early-stage EGFR-mutated non-small cell lung cancer and their care partners gain confidence in their ability to work with and talk to their doctor and healthcare team about a treatment plan.

You will learn about:

What an EGFR mutation is
Testing to learn more about your mutation
Different treatments for early-stage EGFR-mutated non-small cell lung cancer

SUBSCRIBE FOR FREE: Apple Podcasts

Certain treatments mentioned may include medications not approved by the US Food and Drug Administration (FDA) for EGFR-mutated non-small cell lung cancer but are recommended by the National Comprehensive Cancer Network (NCCN).

SUBSCRIBE FOR FREE: Apple Podcasts

Join Danielle from GO2 as she talks to Dr Joshua Sabari and Larry Gershon about early-stage EGFR-mutated non-small cell lung cancer and treatment plans.

LISTEN FROM YOUR APP: Apple Podcasts

Authors and Disclosures

Host

Danielle Hicks

Chief Patient OfficerGO2 Foundation for Lung CancerSan Carlos, California Danielle Hicks, has the following relevant financial relationships:Consultant or advisor for: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Merck.

Panelists

Joshua K. Sabari, MD

Attending PhysicianThoracic Medical OncologyAssistant Professor of MedicineNew York University Langone Health Perlmutter Cancer CenterNew York, New York Joshua K. Sabari, MD, has the following relevant financial relationships:Consultant or advisor for: AbbVie Inc.; AstraZeneca Pharmaceuticals LP; Bristol Myers Squibb Company; Genentech; Janssen; Jazz Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mirati; Navire; Pfizer, Inc.; Regeneron Pharmaceuticals, Inc.; Revolution Medicines; Sanofi Genzyme; Takeda.Research funding from: Janssen; Lilly; Loxo Oncology; Mirati; Regeneron Pharmaceuticals, Inc.

Larry Gershon

Patient AdvocatePalo Alto, California Larry Gershon, has the following relevant financial relationships:Consultant or advisor for: Boehringer Ingelheim Pharmaceuticals, Inc.

Editor

Ashwin Prasanna

Learning Designer, Medscape, LLC. Ashwin, Prasanna, has no relevant financial relationships.